CRNX Stock Forecast & Price Target

Crinetics Pharmaceuticals has shown a significant increase in revenue estimates for its primary product, Palsonify, with projections rising from $49 million to $62 million for 2026, reflecting strong market demand and favorable patient outcomes. The company reported over $5 million in net product revenue for Palsonify in the fourth quarter of 2025, surpassing both consensus expectations and internal estimates, which bolsters confidence in its sales trajectory moving forward. Furthermore, the pipeline's robust development framework is anticipated to yield pivotal readouts in 2027, further enhancing the company's financial outlook as it aims to improve treatment options for patients with rare endocrine diseases.

Crinetics Pharmaceuticals faces significant financial challenges, as the company is expected to incur net losses until commercialization and potentially throughout the early launch phase of its products. The presence of liver enzyme elevations presents a near-term overhang that could hinder the commercial uptake of its lead product, Palsonify, given the difficulty in differentiating it from existing treatment options. Furthermore, a revision of peak sales estimates in the EU from $500 million to $300 million underscores the concern about the company's potential revenue generation capabilities in a competitive market.